SPOTLIGHT -
EP. 1: The Broad Spectrum of Myelodysplastic Syndrome
EP. 2: WHO Criteria and Diagnosis in MDS
EP. 3: Diagnostic Challenges: When Is It MDS
EP. 4: MDS Risk Stratification and Treatment
EP. 5: Comorbidities, Mutations, and Risk in MDS
EP. 6: Treatment Goals for Lower Risk MDS
EP. 7: Parameters for Blood Transfusion in MDS
EP. 8: Options in Low-Risk Myelodysplastic Syndrome
EP. 9: Management of Patients with MDS and Cytopenias
EP. 10: Treatment Goals for Higher Risk MDS
EP. 11: Hypomethylating Agents in MDS: Factors to Consider
EP. 12: Rationale for Combination Therapy in MDS
EP. 13: Emerging Approaches in MDS Treatment
Up-Front Osimertinib Provides Comparable OS, Improved Brain PFS Vs Sequential Gefitinib/Osimertinib in EGFR+ NSCLC
Dr Nasioudis on the Use of NGS to Identify the Molecular Profile of Endometroid Ovarian Cancer
Dr Buckingham on the Use of Patient-reported Outcomes to Predict Frailty in Patients With Ovarian Cancer
Dr Slomovitz on the Investigation of Letrozole Plus Ribociclib in Low-Grade Serous Ovarian Carcinoma
